{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Progression of disease"},{"measurements":[{"groupId":"OG000","value":"6"}],"title":"Stable disease"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"N/A - off study before disease evaluation"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Did not start study treatment"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"IMWG Criteria for Response, Progression and Relapse in Multiple Myeloma Patients","groups":[{"description":"Eligible patients will receive cabozantinib as a tablet, orally daily. One cycle is defined as 28 days. Myeloma response will be assessed by IMWG criteria after each cycle. The DLT evaluation period will be six weeks. This trial will be a standard 3 by 3 dose escalation design, where three daily dose levels (20mg, 40mg, and 60mg) will be investigated.","id":"OG000","title":"Cabozantinib (XL184)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"9 participants are evaluable. 2 participants never started treatment.","reportingStatus":"POSTED","timeFrame":"1 year","title":"Overall Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}